
The FDA has awarded accelerated approval to Roche and Blueprint Medicines’ Gavreto (pralsetinib) for the treatment of advanced or metastatic …
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns

